Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY to make an "Oral Presentation" on Bracelet-1 at ASCO

<< Previous

Bullboard Posts

Next >>

Comment by fox7mfon Apr 27, 2023 9:02am

192 Views

Post# 35416596

RE:ONCY to make an "Oral Presentation" on Bracelet-1 at ASCO

A nice little tidbit of excellent/important news. Oncy has been granted important realestate at ASCO, that certainly doesn't just go to any biotech. They could/should be presenting monumental data. Game changing. The BOD now must concentrate on delivering a steady stream of NR'S to bring shareholder value. What happens over the next month, and what is released at ASCO could very well lead to Noteables $10b-$15b buyout. My opinion. Good luck everyone.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale